ArticleHealth science reports2026
Comparison of the Effectiveness of Ivermectin 1% Cream and Ketoconazole 2% Cream in Treating Facial Seborrheic Dermatitis: A Double-Blind, Randomized, Controlled Clinical Trial.
Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: Seborrheic dermatitis (SD) is a common, chronic, and relapsing disease affecting the patients' quality of life. Expanding the treatment armamentarium provides better care for patients. Topical ivermectin, an anti-inflammatory and anti-parasitic agent, is a potential treatment for SD. We designed this study to assess the effectiveness of topical ivermectin in treating facial SD. Methods: Thirty-six out of 40 patients completed this double-blind, randomized controlled study. In the first group, 17 patients received 2% ketoconazole cream twice a day and cold cream at night, and in the second group, 19 patients applied 1% ivermectin cream once nightly and cold cream twice daily. At the beginning of the study, 1 and 2 months later, the parameters of SEborrheic Dermatitis Area and Severity Index (SEDASI), erythema index, pruritus severity, and quality of life (DLQI score) were measured in both groups. Results: Repeated measures analysis of variance showed that both ivermectin and ketoconazole significantly improved SEDASI scores and erythema index over time ( Conclusion: Ivermectin cream is a safe and effective treatment for facial SD, and is as effective as topical ketoconazole in reducing SEDASI score, erythema index, itch score, and DLQI score of SD patients. Topical ivermectin could be added to the therapeutic armamentarium of SD.(Iranian Registry of Clinical Trials registration No: IRCT20210222050452N1).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.